BR112023024162A2 - Terapia oral preferida com undecanoato de testosterona para obter o tratamento de substituição de testosterona - Google Patents

Terapia oral preferida com undecanoato de testosterona para obter o tratamento de substituição de testosterona

Info

Publication number
BR112023024162A2
BR112023024162A2 BR112023024162A BR112023024162A BR112023024162A2 BR 112023024162 A2 BR112023024162 A2 BR 112023024162A2 BR 112023024162 A BR112023024162 A BR 112023024162A BR 112023024162 A BR112023024162 A BR 112023024162A BR 112023024162 A2 BR112023024162 A2 BR 112023024162A2
Authority
BR
Brazil
Prior art keywords
testosterone
preferred oral
replacement treatment
oral therapy
undecanoate
Prior art date
Application number
BR112023024162A
Other languages
English (en)
Portuguese (pt)
Inventor
S Bernstein James
Om Dhingra
Original Assignee
Marius Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marius Pharmaceuticals Llc filed Critical Marius Pharmaceuticals Llc
Publication of BR112023024162A2 publication Critical patent/BR112023024162A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112023024162A 2021-05-19 2022-05-18 Terapia oral preferida com undecanoato de testosterona para obter o tratamento de substituição de testosterona BR112023024162A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163190609P 2021-05-19 2021-05-19
PCT/US2022/029819 WO2022245933A1 (en) 2021-05-19 2022-05-18 Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment

Publications (1)

Publication Number Publication Date
BR112023024162A2 true BR112023024162A2 (pt) 2024-02-06

Family

ID=84140782

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024162A BR112023024162A2 (pt) 2021-05-19 2022-05-18 Terapia oral preferida com undecanoato de testosterona para obter o tratamento de substituição de testosterona

Country Status (10)

Country Link
US (1) US20230398128A1 (https=)
EP (1) EP4340846A4 (https=)
JP (1) JP2024521127A (https=)
KR (1) KR20240027602A (https=)
AU (2) AU2022277557B2 (https=)
BR (1) BR112023024162A2 (https=)
CA (1) CA3219547A1 (https=)
IL (1) IL308658A (https=)
MX (1) MX2023013734A (https=)
WO (1) WO2022245933A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2519230T3 (pl) 2009-12-31 2019-05-31 Marius Pharmaceuticals Llc Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
EP2968137B1 (en) 2013-03-15 2021-11-10 Marius Pharmaceuticals LLC Emulsion formulations
US12403146B2 (en) 2019-10-30 2025-09-02 Marius Pharmaceuticals, Inc. Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2519230T3 (pl) * 2009-12-31 2019-05-31 Marius Pharmaceuticals Llc Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
US20200197412A1 (en) * 2018-12-20 2020-06-25 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
US11564933B2 (en) * 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency

Also Published As

Publication number Publication date
AU2022277557A1 (en) 2023-06-08
JP2024521127A (ja) 2024-05-28
AU2024227786A1 (en) 2024-11-21
CA3219547A1 (en) 2022-11-24
WO2022245933A1 (en) 2022-11-24
IL308658A (en) 2024-01-01
KR20240027602A (ko) 2024-03-04
EP4340846A1 (en) 2024-03-27
WO2022245933A8 (en) 2023-01-26
MX2023013734A (es) 2024-02-07
US20230398128A1 (en) 2023-12-14
EP4340846A4 (en) 2025-04-02
AU2022277557B2 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
BR112023024162A2 (pt) Terapia oral preferida com undecanoato de testosterona para obter o tratamento de substituição de testosterona
CO2021006672A2 (es) Moduladores de nlrp3
BR112021006458A2 (pt) composto de isoindolina, seu método de preparação, composição farmacêutica e uso
MX2025007468A (es) Composiciones y metodos para el manejo de trastornos
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
GT200900175A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
CO6300949A2 (es) Regimen de dosificacion asociado con esteres de paliperidona inyectables de accion prolongada
BR112021020409A2 (pt) Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase
PA8493801A1 (es) Moduladores del receptor glucocorticoide
BR112018068512A2 (pt) métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
MX2022016463A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
CL2020000085A1 (es) Moduladores de nlrp3.
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
BR112022010879A2 (pt) Métodos e composições para tratamento de edema refratário a diuréticos orais
BR112023025916A2 (pt) Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
PH12022551052A1 (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
UY40701A (es) Protacs para irak4
EP4385564A3 (en) Dosing regimens associated with extended release paliperidone injectable formulations

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]